Andarine, also known as S-4, is an investigational compound categorized as a selective androgen receptor modulator (SARM). SARMs are designed to produce similar effects to anabolic steroids, such as increased muscle and bone density, but with reduced androgenic side effects in non-skeletal muscle tissues. Andarine was initially developed by GTX, Inc. for the treatment of conditions like muscle wasting and osteoporosis. Its mechanism involves selectively binding to androgen receptors in target tissues. While it has been the subject of preclinical and some clinical research, Andarine is not approved for human use by regulatory bodies like the FDA or EMA. It is often encountered in the context of research chemicals or illicit performance-enhancing substances. Due to its unapproved status, there is limited clinical data on its long-term safety and efficacy in humans (source: PubChem, DrugBank).
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["- PubChem Compound Summary (National Library of Medicine)", "- DrugBank Online", "- Scientific literature on Selective Androgen Receptor Modulators (SARMs)", "- World Anti-Doping Agency (WADA) Prohibited List"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the hormone category or studied for the same goals.